Novavax files for emergency use listing of Covid-19 vaccine with WHO




Biotechnology firm Novavax Inc said it has completed the rolling submission for the emergency use listing (EUL) of its Covid-19 vaccine candidate to the (WHO).


Earlier on Monday, Novavax and its partner (SII) had said that they had received the first emergency use authorisation (EUA) for Covid-19 vaccine in Indonesia.





“The company has now completed the submission to (WHO) of all modules required for the regulatory evaluation of NVX-CoV2373, the company’s recombinant nanoparticle protein-based Covid-19 vaccine with Matrix-M adjuvant,” Novavax Inc said in a statement on Thursday.

 



The chemistry, manufacturing and controls module submitted to WHO, as well as other regulatory agencies worldwide, leverages Novavax’ manufacturing partnership with the SII, the world’s largest vaccine manufacturer by volume, it added.


Novavax will make further submissions to enable vaccine supply from additional manufacturing sites in Novavax’ global supply chain. The filing by Novavax is in addition to a previous filing to WHO by Novavax and SII, the company said.


“Today’s submission reflects our continued focus on accelerating access and equitable distribution as we work to bring our vaccine to people in need around the globe,” Novavax President and Chief Executive Officer Stanley C Erck said.


The grant of WHO EUL is a pre-requisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies, Novavax Inc said.


The company continues to work closely with governments, regulatory authorities and non-governmental organisations in its commitment to ensuring equitable global access to its Covid-19 vaccine, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link